|
1
|
Bosetti C, Turati F and La Vecchia C:
Hepatocellular carcinoma epidemiology. Best Pract Res Clin
Gastroenterol. 28:753–770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Margini C and Dufour JF: The story of HCC
in NAFLD: From epidemiology, across pathogenesis, to prevention and
treatment. Liver Int. 36:317–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xie DY, Ren ZG, Zhou J, Fan J and Gao Q:
Critical appraisal of Chinese 2017 guideline on the management of
hepatocellular carcinoma. Hepatobiliary Surg Nutr. 6:387–396. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li C, Li R and Zhang W: Progress in
non-invasive detection of liver fibrosis. Cancer Biol Med.
15:124–136. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haruyama Y and Kataoka H: Glypican-3 is a
prognostic factor and an immunotherapeutic target in hepatocellular
carcinoma. World J Gastroenterol. 22:275–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fleming BD and Ho M: Glypican-3 targeting
immunotoxins for the treatment of liver cancer. Toxins (Basel).
8:E2742016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Capurro M, Martin T, Shi W and Filmus J:
Glypican-3 binds to Frizzled and plays a direct role in the
stimulation of canonical Wnt signaling. J Cell Sci. 127:1565–1575.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hippo Y, Watanabe K, Watanabe A,
Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y,
Nakano K, et al: Identification of soluble NH2-terminal fragment of
glypican-3 as a serological marker for early-stage hepatocellular
carcinoma. Cancer Res. 64:2418–2423. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang L, Pan L, Yao M, Cai Y, Dong Z and
Yao D: Expression of oncofetal antigen glypican-3 associates
significantly with poor prognosis in HBV-related hepatocellular
carcinoma. Oncotarget. 7:42150–42158. 2016.PubMed/NCBI
|
|
10
|
Kaseb AO, Hassan M, Lacin S, Abdel-Wahab
R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, et
al: Evaluating clinical and prognostic implications of Glypican-3
in hepatocellular carcinoma. Oncotarget. 7:69916–69926. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clark JD, Gebhart GF, Gonder JC, Keeling
ME and Kohn DF: Special Report: The 1996 guide for the care and use
of laboratory animals. ILAR J. 38:41–48. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sharma D, Subbarao G and Saxena R:
Hepatoblastoma. Semin Diagn Pathol. 34:192–200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimizu H, Nakagawa M, Todaka N, Imaizumi
K, Kurosawa Y, Maruyama T, Okumura CJ, Shibata T, Tanaka Y, Sato Y,
et al: Improving the quality of a recombinant rabbit monoclonal
antibody against PLXDC2 by optimizing transient expression
conditions and purification method. Protein Expr Purif. 146:27–33.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ni WW, Huang W, Wu DQ, Zhou YJ, Ji CM, Cao
MD, Guo M, Sun JL and Wei JF: Expression and purification of a
major allergen, Pla a 1, from Platanus acerifolia pollen and the
preparation of its monoclonal antibody. Mol Med Rep. 16:2887–2892.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi J, Zhang DL, Cui ZC and Wang HM:
Preparation and application of a novel monoclonal antibody specific
for human B7-H3. Mol Med Rep. 14:943–948. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Simons A, Shaffer LG and Hastings RJ:
Cytogenetic nomenclature: Changes in the ISCN 2013 compared to the
2009 edition. Cytogenet Genome Res. 141:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Turkes F and Chau I: Ramucirumab and its
use in the treatment of hepatocellular carcinoma. Future Oncol.
2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Capurro M, Wanless IR, Sherman M, Deboer
G, Shi W, Miyoshi E and Filmus J: Glypican-3: A novel serum and
histochemical marker for hepatocellular carcinoma.
Gastroenterology. 125:89–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Midorikawa Y, Ishikawa S, Iwanari H,
Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M and
Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma,
modulates FGF2 and BMP-7 signaling. Int J Cancer. 103:455–465.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamauchi N, Watanabe A, Hishinuma M,
Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M,
Makuuchi M, et al: The glypican 3 oncofetal protein is a promising
diagnostic marker for hepatocellular carcinoma. Mod Pathol.
18:1591–1598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Filmus J, Church JG and Buick RN:
Isolation of a cDNA corresponding to a developmentally regulated
transcript in rat intestine. Mol Cell Biol. 8:4243–4249. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li M, Choo B, Wong ZM, Filmus J and Buick
RN: Expression of OCI-5/glypican 3 during intestinal morphogenesis:
Regulation by cell shape in intestinal epithelial cells. Exp Cell
Res. 235:3–12. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshikawa T, Nakatsugawa M, Suzuki S,
Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S
and Nakatsura T: HLA-A2-restricted glypican-3 peptide-specific CTL
clones induced by peptide vaccine show high avidity and
antigen-specific killing activity against tumor cells. Cancer Sci.
102:918–925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Attallah AM, El-Far M, Omran MM,
Abdelrazek MA, Attallah AA, Saeed AM and Farid K: GPC-HCC model: A
combination of glybican-3 with other routine parameters improves
the diagnostic efficacy in hepatocellular carcinoma. Tumour Biol.
37:12571–12577. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishiguro T, Sugimoto M, Kinoshita Y,
Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H,
Hamakubo T, et al: Anti-glypican 3 antibody as a potential
antitumor agent for human liver cancer. Cancer Res. 68:9832–9838.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakano K, Orita T, Nezu J, Yoshino T,
Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T,
Hamakubo T, et al: Anti-glypican 3 antibodies cause ADCC against
human hepatocellular carcinoma cells. Biochem Biophys Res Commun.
378:279–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang YF and Ho M: Humanization of
high-affinity antibodies targeting glypican-3 in hepatocellular
carcinoma. Sci Rep. 6:338782016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakano K, Ishiguro T, Konishi H, Tanaka M,
Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K, et al:
Generation of a humanized anti-glypican 3 antibody by CDR grafting
and stability optimization. Anticancer Drugs. 21:907–916. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ishiguro T, Kinoshita Y and Sugimoto M:
Anti-glypican3 antibody for treatment of human liver cancer.
Proceedings of the 101st annual meeting of the AACR. April 17–21.
Abstract #A2426 Washington, DC: 2010
|
|
30
|
Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S,
Kobayashi S, Morizane C, Suzuki I, Yamamoto S and Furuse J:
Japanese phase I study of GC33, a humanized antibody against
glypican-3 for advanced hepatocellular carcinoma. Cancer Sci.
105:455–462. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Abou-Alfa GK, Puig O, Daniele B, Kudo M,
Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, et al:
Randomized phase II placebo controlled study of codrituzumab in
previously treated patients with advanced hepatocellular carcinoma.
J Hepatol. 65:289–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yin J, Li G, Ren X and Herrler G: Select
what you need: A comparative evaluation of the advantages and
limitations of frequently used expression systems for foreign
genes. J Biotechnol. 127:335–347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Köhler G and Milstein C: Continuous
cultures of fused cells secreting antibody of predefined
specificity. Nature. 256:495–497. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang YL, Wang YL, Mu H, Liu T, Chen XB and
Shen ZY: Enhanced specific cytotoxicity of DCs transfected with
GPC3 gene co-cultured with CIKs to GPC3-expressing hepatocellular
carcinoma cells. Mol Med Rep. 11:3361–3367. 2015. View Article : Google Scholar : PubMed/NCBI
|
